The purpose of this study is to track the clinical safety and effectiveness of the Pericardium Covered Stent in "real world" use.

This is a multi-center registry of 75 patients treated with the Over and Under/Aneugraft Pericardium Covered Stent (PCS) (IGTI, Israel). The registry will involve the collection of demographic, clinical, and angiographic data on the treated patient population, including in-hospital, 30 day, 6-month, 1 year, 2 years and 3 years clinical follow-up data.

Inclusion Criteria:

• Patient is older than 18 years

• Patient must be available for follow-up

• Patient must be fully informed, provided with the patient information sheet and sign the Informed Consent Form prior to the procedure.

• The lesion to be treated should be suitable for treatment with a PCS in that:

  • A. A suitable length and diameter PCS should be available
  • B. For SVG disease a single or multiple PCS may be used
  • C. For native coronary artery aneurysms the operator should be confident that the aneurysm may be excluded by the implantation of a single PCS

Exclusion Criteria:

• Significant co-morbidity precluding clinical follow-up.
• Pregnancy; pregnancy test negative in women with child bearing potential
• Acute ST-elevation myocardial infarction within the preceding 48 hours
• Previous stent implantation in the target vessel
• Left main coronary artery disease
• Contra-indication to dual anti-platelet therapy.
• Planned surgery which will lead to discontinuation of antiplatelet therapy
• Thrombocytopenia (<100,000/mm3)
• Ejection fraction <30%.
• Renal failure (creatinine >180 µmol/L [2 mg/dL])
• Prior brachytherapy
• Recipient of heart transplant
• Acute infections

Patients presenting for PCI.